logo-loader
viewMedlab Clinical Ltd

Medlab Clinical signs second international distribution deal for NanaBis

The agreement is with a major international Thai pharmaceutical company.

deal concept
This follows a similar deal with Canada’s fourth largest generic pharmaceutical company

Medlab Clinical Ltd (ASX:MDC) has executed a heads of agreement with Thai-listed Mega Lifesciences (BKK:MEGA) for the further global distribution of NanaBis™. 

The terms of the agreement provide for both parties to negotiate various commercial terms involving potential global territories for NanaBis™. 

NanaBis is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is delivered into the body using Medlab’s patented sub-micron delivery platform NanoCelle™.

NanaBis is a buccal (side of cheek) spray currently in the second stage of an Australian advanced cancer pain trial.

Patients can access it under the government’s Special Access Scheme and it is currently before several regulatory agencies for potential fast track drug approval pathways.

READ: Medlab CEO presents clinical NanaBis update to medical practitioners

Medlab’s CEO Dr Sean Hall said: “NanaBis™ is in an exciting stage of its development as the company looks to fast track global drug approval pathways.

“This Heads of Agreement signifies real intent and interest for a true global pharmaceutical company to enter legitimate science as it relates to cannabis that has been research focused into a serious condition: cancer pain.

He added: “being able to collaborate with global pharmaceutical companies like Mega allows MDC the opportunity to expand NanaBis™ quicker in global territories.”

READ: Medlab Clinical collaborates with Chronic Pain Australia

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.

NanaBis™ is currently in clinical trial at Royal North Shore Hospital.

Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Proactive caught up with Medlab earlier this month for an update.

Quick facts: Medlab Clinical Ltd

Price: 0.435 AUD

ASX:MDC
Market: ASX
Market Cap: $93.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

2 min read